CA2561293A1 - Treatment of incontinence - Google Patents

Treatment of incontinence Download PDF

Info

Publication number
CA2561293A1
CA2561293A1 CA002561293A CA2561293A CA2561293A1 CA 2561293 A1 CA2561293 A1 CA 2561293A1 CA 002561293 A CA002561293 A CA 002561293A CA 2561293 A CA2561293 A CA 2561293A CA 2561293 A1 CA2561293 A1 CA 2561293A1
Authority
CA
Canada
Prior art keywords
incontinence
treatment
venlafaxine
humans
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002561293A
Other languages
French (fr)
Other versions
CA2561293C (en
Inventor
Karl Bruce Thor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from CA002136120A external-priority patent/CA2136120C/en
Publication of CA2561293A1 publication Critical patent/CA2561293A1/en
Application granted granted Critical
Publication of CA2561293C publication Critical patent/CA2561293C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Urinary incontinence in humans is treated by administration of venlafaxine, or a pharmaceutically acceptable acid addition salt thereof.
CA002561293A 1993-11-24 1994-11-18 Treatment of incontinence Expired - Lifetime CA2561293C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15812193A 1993-11-24 1993-11-24
US08/158,121 1993-11-24
CA002136120A CA2136120C (en) 1993-11-24 1994-11-18 Treatment of incontinence

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002136120A Division CA2136120C (en) 1993-11-24 1994-11-18 Treatment of incontinence

Publications (2)

Publication Number Publication Date
CA2561293A1 true CA2561293A1 (en) 1995-05-25
CA2561293C CA2561293C (en) 2008-03-18

Family

ID=37451524

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002561293A Expired - Lifetime CA2561293C (en) 1993-11-24 1994-11-18 Treatment of incontinence

Country Status (1)

Country Link
CA (1) CA2561293C (en)

Also Published As

Publication number Publication date
CA2561293C (en) 2008-03-18

Similar Documents

Publication Publication Date Title
CA2259012A1 (en) S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
NO2005004I1 (en) Duloxetine and its pharmaceutically acceptable acid addition salts, especially duloxetine hydrochloride
CA2160366A1 (en) Risperidone pamoate
CA2213339A1 (en) Method of treating adenosine depletion
EP0815860A3 (en) Terfenadine carboxylate and the treatment of allergic disorders
CA2263561A1 (en) Thienopyrimidines
CA2130805A1 (en) Use of mannose phosphates for the treatment of fibrotic disorders
EG20273A (en) Process for preparing of pyrazolopyrimidines and their use in the treatment of stress related and other diseases
RO116342B1 (en) Oral liquid pharmaceutical composition
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
CA2154103A1 (en) Treatment of Mucous Membrane Disease, Trauma or Condition and for the Relief of Pain
CA2132416A1 (en) Use of transglutaminase inhibitor for the treatment of scar tissue
AU1117092A (en) Treatment of lower urinary tract disorders
CA2113916A1 (en) 6-Chloro-5-Fluoro-3-(2-Thenoyl)-2-Oxindole-1-Carboxamide as an Analgesic and Anti-Inflammatory Agent
WO1997005862A3 (en) Use of basic amino acids and derivatives for lowering ceramide levels
CA2139385A1 (en) Products containing g-csf and tnf binding protein
AU2713992A (en) Therapeutic agent
WO2001010427A3 (en) Use of anti-muscarinic agents for treating skin disorders
EP0342587A3 (en) Thienotriazolodiazepine compounds and pharmaceutical uses thereof
CA2120319A1 (en) Pharmaceutical for the treatment of skin disorders
CA2018791A1 (en) Hair treatment composition
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
CA2561293A1 (en) Treatment of incontinence

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20141118